Prelude Capital Management’s AbbVie ABBV Stock Holding History

Prelude Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,100	Closed	-$761K	–	1502
2020 Q4	$761K	Hold	7,100	–	–	0.02%	565
2020 Q3	$622K	Hold	7,100	–	–	0.03%	385
2020 Q2	$697K	Sell	7,100 -400	-5%	-$35.2K	0.04%	398
2020 Q1	$571K	Sell	7,500 -33,600	-82%	-$2.86M	0.04%	301
2019 Q4	$3.64M	Buy	41,100 +27,100	+194%	+$2.25M	0.14%	98
2019 Q3	$1.06M	Sell	14,000 -36,000	-72%	-$2.47M	0.05%	320
2019 Q2	$3.64M	Buy	+50,000	New	+$3.93M	0.18%	90
2019 Q1	–	Sell	-100	Closed	-$9K	–	1721
2018 Q4	$9K	Buy	+100	New	+$8.79K	﹤0.01%	1383
2018 Q2	–	Sell	-200	Closed	-$19K	–	1616
2018 Q1	$19K	Buy	+200	New	+$22K	﹤0.01%	1271
2014 Q2	–	Sell	-1,500	Closed	-$77K	–	1870
2014 Q1	$77K	Buy	+1,500	New	+$75.8K	0.01%	1130

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prelude Capital Management's ABBV Position: Q1 2026 in Review

Prelude Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 3,184 shares — an estimated $728K sold.

Prelude Capital Management first reported a position in ABBV in Q1 2015 and held it in 21 quarters. The position peaked at $2.67M in Q2 2021. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Prelude Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 3,184 AbbVie shares in Q1 2026, an estimated $728K.
Prelude Capital Management first reported a position in AbbVie in Q1 2015 and held it in 21 quarters.
Prelude Capital Management's AbbVie position peaked at $2.67M in Q2 2021.
4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.